Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Tasmar

Tasmar 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-086561 · Präparat HOS-083306

Catechols and other drugs metabolised by catechol-O-methyltransferase (COMT) Tolcapone may influence the pharmacokinetics of drugs metabolised by COMT. No effects were seen on the pharmacokinetics of the COMT substrate carbidopa. An interaction was observed with benserazide, which may lead to increased levels of benserazide and its active metabolite. The magnitude of the effect was dependent on the dose of benserazide. The plasma concentrations of benserazide observed after co-administration of tolcapone and benserazide-25 mg/levodopa were still within the range of values observed with levodopa/benserazide alone. On the other hand, after coadministration of tolcapone and benserazide-50 mg/levodopa the benserazide plasma concentrations could be increased above the levels usually observed with levodopa/benserazide alone. The effect of tolcapone on the pharmacokinetics of other drugs metabolised by COMT such as -methyldopa, dobutamine, apomorphine, adrenaline and isoprenaline have not been evaluated. The prescriber should be observant of adverse reactions caused by putative increased plasma levels of these drugs when combined with Tasmar.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levodopa (HOS-086559) methyldopa (HOS-086564) dobutamine (HOS-086565) apomorphine (HOS-086566) carbidopa (HOS-086562) benserazide (HOS-086563) lead (HOS-085592)